Aroa Biosurgery Limited (ASX:ARX) Insider James (Jim) McLean Buys 50,000 Shares of Stock

Aroa Biosurgery Limited (ASX:ARXGet Free Report) insider James (Jim) McLean purchased 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were acquired at an average cost of A$0.75 ($0.48) per share, with a total value of A$37,500.00 ($24,193.55).

Aroa Biosurgery Price Performance

The company has a debt-to-equity ratio of 6.97, a quick ratio of 8.39 and a current ratio of 9.88.

Aroa Biosurgery Company Profile

(Get Free Report)

Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and sells medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction.

Further Reading

Receive News & Ratings for Aroa Biosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aroa Biosurgery and related companies with MarketBeat.com's FREE daily email newsletter.